
Ji-Sun Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4724242/publications.pdf Version: 2024-02-01



ILSUN KIM

#	Article	IF	CITATIONS
1	Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. Nature Communications, 2017, 8, 15090.	12.8	127
2	Critical Issues in the Development of Immunotoxins for Anticancer Therapy. Journal of Pharmaceutical Sciences, 2020, 109, 104-115.	3.3	64
3	Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth. Science Advances, 2020, 6, eaay2174.	10.3	51
4	Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. Journal of Controlled Release, 2016, 235, 165-175.	9.9	42
5	Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells by an enhanced split GFP complementation assay. Biochemical and Biophysical Research Communications, 2015, 467, 771-777.	2.1	34
6	Engineering of a tumor cell–specific, cytosol-penetrating antibody with high endosomal escape efficacy. Biochemical and Biophysical Research Communications, 2018, 503, 2510-2516.	2.1	13
7	Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Cancer Letters, 2021, 507, 97-111.	7.2	7
8	Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody. Biochemical and Biophysical Research Communications, 2021, 573, 35-41.	2.1	7